Supplied as a lyophilised powder to reconstitute
Metabolic & Weight
At a glance
Ten answers, each one line. Open any row for the detail behind it.
What it does Boehringer Ingelheim's entry in the glucagon-combination race.
Boehringer Ingelheim's entry in the glucagon-combination race. Its most interesting phase 2 result was not weight loss but liver histology — a majority of participants with MASH achieved improvement without worsening fibrosis, which is a harder endpoint than weight.
Half-life ~6 days — Documented
~6 days
Typical studied dose No established dose. Each trial protocol fixes its own and publishes it… — Depends on the study
No established dose. Each trial protocol fixes its own and publishes it in the registry entry, under medical supervision that is part of the dose. There is no approved amount for use outside a study.
How often it is used Whatever the protocol specifies. The registry entry for a given study… — Depends on the study
Whatever the protocol specifies. The registry entry for a given study states its interval; nothing establishes one outside a study.
How it is taken Subcutaneous, once weekly (investigational) — Documented
Subcutaneous, once weekly (investigational)
Main side effects Not approved anywhere · Grey-market sale · High GI adverse event rate — Carries serious risk
Not approved anywhere — Phase 3 is ongoing; efficacy and safety conclusions remain provisional.
Grey-market sale — Sold illicitly as a research peptide despite having no approved use.
High GI adverse event rate — Nausea and vomiting were common and drove discontinuations in phase 2.
Storage before mixing As a sealed lyophilised powder, refrigerated is typical and a freezer…
As a sealed lyophilised powder, refrigerated is typical and a freezer suits long storage; both should be dark and dry. A dry powder tolerates a few days out of the cold far better than anything in solution — which is why it ships that way.
Shelf life after mixing Once mixed it is refrigerated and treated as short-lived. Bacteriostatic…
Once mixed it is refrigerated and treated as short-lived. Bacteriostatic water contains a preservative and buys the longer window; sterile water contains none and buys a much shorter one. Peptides in solution also degrade on their own, so the container is only half the question.
Evidence level 3/5 · Moderate — Depends on the study
Small or early-phase human trials, or good controlled topical human data.
Regulatory status In Clinical Trials — Depends on the study
Phase 3 (SYNCHRONIZE program) in obesity and in metabolic dysfunction-associated steatohepatitis. Not approved. Investigational. Not approved by any regulator.
Overview
Boehringer Ingelheim's entry in the glucagon-combination race. Its most interesting phase 2 result was not weight loss but liver histology — a majority of participants with MASH achieved improvement without worsening fibrosis, which is a harder endpoint than weight.
Investigational — not approvedInvestigational. Not approved by any regulator.
| Regulatory status | Phase 3 (SYNCHRONIZE program) in obesity and in metabolic dysfunction-associated steatohepatitis. Not approved. |
|---|---|
| Drug class | Dual glucagon / GLP-1 receptor agonist |
| Route | Subcutaneous, once weekly (investigational) |
| Half-life | ~6 days |
| Evidence rating |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
Small or early-phase human trials, or good controlled topical human data. |
| Studied in | Phase 2 obesity and MASH trials; SYNCHRONIZE phase 3 program in obesity, obesity with type 2 diabetes, and MASH. |
Survodutide sequence & structure
Survodutide is a 29-residue linear peptide with a C-terminal amide, carrying a fatty-acid side chain, non-standard residues; molecular weight 4,231.69 Da.
* K: Gly-Gly-Ser-Gly-Ser-Gly-γGlu-C18-diacid
[bracketed] = non-standard residue* = side-chain modification
| Three-letter | H-His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys(Gly-Gly-Ser-Gly-Ser-Gly-γGlu-C18 diacid)-Trp-Leu-Glu-Ser-Ala-NH2 |
|---|---|
| Length | 29 amino acid residues |
| Modifications |
|
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4,231.69 Da (average, free base) |
| Identifiers | CAS 2805997-46-8 · PubChem CID 168429725 · UniProt P01275 |
| Sources | WHO Proposed INN List 128 (survodutidum, full chemical name)FDA/NCATS GSRS substance record, UNII 2ALA66NS64 (subunit sequences and Lys24 linkage)PubChem CID 168429725 (formula, MW, CAS)UniProt P01275 — human pro-glucagon (parent sequence) |
Glucagon(1-29) backbone; the WHO INN name reads "L-histidyl-1-aminocyclobutanoyl-...", confirming a cyclobutane amino acid (Ac4c) at position 2 rather than the Aib that many vendor pages state. The Lys24 side chain is N6-[N-(17-carboxyheptadecanoyl)-L-γ-glutamylglycyl-L-serylglycyl-L-serylglycylglycyl], i.e. Gly-Gly-Ser-Gly-Ser-Gly then γGlu then the C18 diacid reading outward from the lysine (FDA GSRS records the spacer as subunit 2 "GSGSGG" joined through its residue 6); vendor pages often print it reversed. MW 4231.69 is calculated from the INN/PubChem formula C192H289N47O61 (PubChem rounds to 4232); CAS 2805997-46-8 has a valid check digit; FDA UNII 2ALA66NS64. The DrugBank ID claimed in earlier drafts (DB18989) could not be verified and was removed.
Record confidence: high — two independent authoritative sources agree on the sequence and modifications. Every sequence on the site is listed with its sources on the peptide sequences index.
How it works
Balanced agonism at the glucagon and GLP-1 receptors. GLP-1 suppresses appetite and improves insulin dynamics; glucagon-receptor activity increases hepatic fat oxidation and energy expenditure, which is why the liver signal is stronger than with GLP-1-only agents.
Evidence base
Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.
- Phase 2 with a biopsy-confirmed liver endpoint — unusually rigorous for this stage.
- Phase 3 results pending.
Benefits and risks, weighed against the evidence
Every entry below carries the strength of the evidence behind it — three bars for strong human data, two for moderate, one for preliminary or preclinical work. The two columns are not equal by design: where a compound has more documented risk than demonstrated benefit, the lists say so.
Reported benefits
3 entries
-
MASH improvement in phase 2
A majority of treated participants achieved histological improvement in steatohepatitis without worsening of fibrosis — a biopsy endpoint, not a surrogate marker.
Evidence: Moderate evidence -
Substantial weight reduction
Phase 2 showed roughly 19% mean weight loss at 46 weeks on the highest dose.
Evidence: Moderate evidence -
Added energy expenditure
The glucagon component provides a thermogenic mechanism GLP-1-only drugs lack.
Evidence: Preliminary
Risks and cautions
5 entries · 2 serious or common
-
Not approved anywhere
Phase 3 is ongoing; efficacy and safety conclusions remain provisional.
Evidence: Serious -
High GI adverse event rate
Nausea and vomiting were common and drove discontinuations in phase 2.
Evidence: Moderate evidence -
Heart rate increase
Observed with glucagon-receptor co-agonism across this drug class.
Evidence: Moderate evidence -
Glycemic uncertainty
Glucagon agonism raises hepatic glucose output; the net effect depends on incretin balance and needs phase 3 confirmation.
Evidence: Moderate evidence -
Grey-market sale
Sold illicitly as a research peptide despite having no approved use.
Evidence: Serious
Counts are not a score. A single serious risk can outweigh several well-supported benefits, and a long benefit list built on preclinical work outweighs nothing at all.
Opinion — what people actually report
4 themes · 1 reported benefit · 1 reported problem
This is the weakest tier on this site. These are themes drawn from public discussion — forums, subreddits and patient threads — not from trials. There is no control group, no denominator, and no way to confirm that what someone injected matched its label. People post when a result is dramatic and when something goes wrong, and rarely when nothing happens, so treat everything below as a description of the conversation rather than of the compound. The bars count how often a thing is said, not how well it is supported.
-
Strong appetite suppression reported Reported benefit. Recurring: Raised regularly, though not by everyone.
Accounts describe an effect people rank alongside the GLP-1/GIP agents, though the number of reports is far smaller.
-
Nausea described as significant Reported problem. Dominant theme: Comes up in most discussions of this compound.
The dominant complaint, and reported as the reason for slow escalation.
-
Very few accounts exist Practical note. Dominant theme: Comes up in most discussions of this compound.
An investigational drug with a thin community footprint. Most discussion is about trial results rather than personal experience.
-
Interest in the liver findings Practical note. Recurring: Raised regularly, though not by everyone.
The MASH trial data attracts a distinct group whose interest is not weight loss.
Where the reports and the evidence part ways
Phase 2 results for weight loss and for MASH resolution are real and encouraging, and the glucagon receptor component is a genuine mechanistic difference from the GLP-1 agents. But this drug has not completed phase 3, has no approval, and the small number of self-reports come from unverified research-chemical supply. The gap here is not between report and evidence so much as between a drug in development and a drug people are already injecting.
Readers on Survodutide
Questions and answers from readers, under generated names. Nothing here has been checked or reviewed by the site and none of it is medical advice. It is the least verified thing on this page — and it is here because people ask each other these things anyway, and most of the other places they can ask are run by sellers.
0 questions · 0 answers
No questions yet. Ask the first one above — it takes one box and an email address.
How names work, and the house rules
Names. Every verified address is given one generated name — two ordinary words — and keeps it. Nobody chooses a name and nobody can take another's. Posts marked desk were written by the site's own editorial desk, usually to open a thread; they carry a generated name like everyone else's and are held to the site's rules, which means they never state an amount.
What is not allowed. Selling, sourcing, vendor names, coupon codes and "message me" — posts that read that way are held and usually removed. Personal medical details you would not want public. Abuse. Instructions framed as what someone else should do.
What this is not. A reader's report of what happened to them is a report, not a finding, and an answer here is one person's view. Nothing in this section changes the evidence rating above it. If something you read here would change what you take, take it to a pharmacist or physician first.
Your data. Delete any post of yours at any time, or remove everything you have written together with your name. Details in the privacy notice.
Who should avoid it
- Use outside a registered clinical trial
If used under medical supervision, monitor
- Not applicable outside trials
Interactions
Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.
- Insulin and sulfonylureas — hypoglycemia risk if combined
- Oral medications with narrow therapeutic windows — delayed gastric emptying alters absorption
Regulatory & legal status
Investigational. Not approved by any regulator.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Survodutide
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Metabolic & Weight
Terms used on this page
- Fibrosis
- Fibrosis is the accumulation of excess extracellular matrix that replaces functional tissue, representing repair that has failed to resolve rather than a separate disease process.
- Phase 2 Trial
- A Phase 2 trial is the first test of a compound in the target patient population, sized to find a workable dose and an early efficacy signal rather than to prove clinical benefit.
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- MASH is the inflammatory form of metabolic fatty liver disease, defined histologically by steatosis with hepatocyte ballooning and lobular inflammation, with or without fibrosis.
- Resting Energy Expenditure (REE)
- Resting energy expenditure is the energy a body uses at rest in a fasted, thermoneutral state, and it accounts for most of daily total energy expenditure.
- Glucagon
- Glucagon is a 29-amino-acid pancreatic alpha-cell hormone that raises blood glucose by driving hepatic glycogenolysis and gluconeogenesis, and also increases energy expenditure.
- Agonist
- An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.